A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Bococizumab (Pf-04950615) In Asian Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Trial Profile

A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Bococizumab (Pf-04950615) In Asian Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms SPIRE-ASIA
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2016 New trial record
    • 01 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment since the company has decided to discontinue the global clinical development of bococizumab, according to a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top